News items related to: News
-
Ending the Epidemic Could Cost Under $40 (per person, per year) – treatment activists say at AIDS2024
Munich, 23 July 2024 – Despite global efforts to end HIV and AIDS, the epidemic has been persistent. In 2022,...
-
Activists at AIDS2024 called on ViiV Healthcare to drop their case in Colombia against Compulsory License on Dolutegravir
On the 24th of July, hundreds of treatment advocates attending AIDS2024 in Munich protested against the companies with “Drop The...
-
Activists block big pharma patent on COVID-19 pill in Russia, but fight not over
Russia’s patent office made a ground-breaking decision to reject a patent application for molnupiravir, a treatment for COVID-19, which was...
-
The Rejection of the Bedaquiline Patent Opposition in Indonesia Raises the Risk of Difficulty in Accessing Optimal TB Therapy
The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB)...
-
Brazilian Community-Based Organization ABIA Bids to Expand HIV Treatment Access by Overriding the Patent on Dolutegravir
The Brazilian Interdisciplinary AIDS Association (ABIA), an advocacy group in Rio de Janeiro, has called on the Ministry of Health...
-
Researchers Reveal Strategies Used by Big Pharma to Monopolize COVID-19 Drugs and Vaccines
Pharmaceutical companies took advantage of the COVID-19 pandemic, ensuring maximum profits and monopolies on life-saving vaccines and drugs, according to...
-
FGEP Files Pre-Grant Patent Opposition for Covid Vaccine Against Pfizer
Fundación Grupo Efecto Positivo (FGEP) has filed a pre-grant patent opposition in a bid to make COVID-19 vaccines accessible and...
-
Activists File Patent Opposition to Challenge COVID-19 Drug Monopoly on Baricitinib
Activists from Morocco, Thailand, and Vietnam have filed patent oppositions to challenge drug manufacturers Incyte and Eli Lilly over the...
-
J & J’s Deal With the Global Drug Facility Disguises the Continued Issue with Access to Bedaquiline to Treat Drug-Resistant Tuberculosis
“This deal is big step backwards for global public health – it allows J & J to keep selling higher-priced...
-
The pandemic is declared finished, but the fight for access never stops
MMA consortium members from Argentina, Brazil, Thailand and EECA region, took action to secure access to molnupiravir. In Argentina, the...
-
Being ahead of the curve: access to Delamanid in Thailand
MMA’s consortium partner, the Thai Network of People Living with HIV/AIDS (TNP+), has filed a third-party observation on a patent...
-
Civil Society Organizations in Brazil fight for better access to Dolutegravir
Brazilian Interdisciplinary AIDS Association (ABIA), along with the Working Group on Intellectual Property (GTPI) of the Brazilian Network for the...
